๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Neoadjuvant chemotherapy for operable breast cancer

โœ Scribed by J. S. D. Mieog; J. A. van der Hage; C. J. H. van de Velde

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
155 KB
Volume
94
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Neoadjuvant chemotherapy in breast cance
Neoadjuvant chemotherapy in breast cancer
โœ H. Charfare; S. Limongelli; A. D. Purushotham ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 153 KB ๐Ÿ‘ 1 views
Residual specimen cellularity after neoa
Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer
โœ F. Peintinger; H. M. Kuerer; S. E. McGuire; R. Bassett; L. Pusztai; W. F. Symman ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 289 KB ๐Ÿ‘ 1 views

## Abstract ## Background Neoadjuvant chemotherapy for breast cancer reduces tumour cellularity, the percentage of the primary tumour area that is composed of invasive tumour cells. Minimal residual tumour cellularity (5 per cent or less of tumour area composed of invasive tumour cells) may be ass

Neoadjuvant chemotherapy in locally adva
Neoadjuvant chemotherapy in locally advanced breast cancer
โœ Singh, Gurpreet; Singh, Deepinder P.; Gupta, Devender; Muralikrishna, Bhavaraju ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 403 KB ๐Ÿ‘ 2 views

Thirty-eight patients with locally advanced breast cancer (Stage HI) were treated over a 3-year period. All patients initially received two cycles of CMF (cyclophosphamide, 100 mg/m2 p.0. dl-14; methotrexate 40mg/m2 intravenously (iv), d l and d8., 5 Fluorouracil 500 mg/m2 iv d l and d8). They were

Subcutaneous mastectomy for primary oper
Subcutaneous mastectomy for primary operable breast cancer
โœ Mr C. P. Hinton; P. J. Doyle; R. W. Blamey; C. J. Davies; H. W. Holliday; C. W. ๐Ÿ“‚ Article ๐Ÿ“… 1984 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 468 KB ๐Ÿ‘ 2 views